149 related articles for article (PubMed ID: 29424557)
1. Proteomic biomarkers for lung cancer progression.
Ren Y; Zhao S; Jiang D; Feng X; Zhang Y; Wei Z; Wang Z; Zhang W; Zhou QF; Li Y; Hou H; Xu Y; Zhou F
Biomark Med; 2018 Mar; 12(3):205-215. PubMed ID: 29424557
[TBL] [Abstract][Full Text] [Related]
2. Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer.
Marrugal Á; Ojeda L; Paz-Ares L; Molina-Pinelo S; Ferrer I
Dis Markers; 2016; 2016():2138627. PubMed ID: 27445423
[TBL] [Abstract][Full Text] [Related]
3. Application of proteomics in non-small-cell lung cancer.
Cho WC
Expert Rev Proteomics; 2016; 13(1):1-4. PubMed ID: 26577456
[TBL] [Abstract][Full Text] [Related]
4. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
[TBL] [Abstract][Full Text] [Related]
5. Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma.
Ağababaoğlu İ; Önen A; Demir AB; Aktaş S; Altun Z; Ersöz H; Şanl A; Özdemir N; Akkoçlu A
Medicine (Baltimore); 2017 Feb; 96(6):e5903. PubMed ID: 28178129
[TBL] [Abstract][Full Text] [Related]
6. Prediction of pathologic stage in non-small cell lung cancer using machine learning algorithm based on CT image feature analysis.
Yu L; Tao G; Zhu L; Wang G; Li Z; Ye J; Chen Q
BMC Cancer; 2019 May; 19(1):464. PubMed ID: 31101024
[TBL] [Abstract][Full Text] [Related]
7. Proteomic biomarkers of non-small cell lung cancer patients.
Baran K; Brzeziańska-Lasota E
Adv Respir Med; 2021; 89(4):419-426. PubMed ID: 34494245
[TBL] [Abstract][Full Text] [Related]
8. Nuclear TAZ activity distinctly associates with subtypes of non-small cell lung cancer.
Wang Y; Han Y; Guo Z; Yang Y; Ren T
Biochem Biophys Res Commun; 2019 Feb; 509(3):828-832. PubMed ID: 30638934
[TBL] [Abstract][Full Text] [Related]
9. Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.
Liu X; Chen L; Zhang T
Cancer Control; 2018; 25(1):1073274818778001. PubMed ID: 29843532
[TBL] [Abstract][Full Text] [Related]
10. Identification of serum proteome components associated with progression of non-small cell lung cancer.
Pietrowska M; Jelonek K; Michalak M; Roś M; Rodziewicz P; Chmielewska K; Polański K; Polańska J; Gdowicz-Kłosok A; Giglok M; Suwiński R; Tarnawski R; Dziadziuszko R; Rzyman W; Widłak P
Acta Biochim Pol; 2014; 61(2):325-31. PubMed ID: 24872961
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
[TBL] [Abstract][Full Text] [Related]
12. miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke.
Babu N; Advani J; Solanki HS; Patel K; Jain A; Khan AA; Radhakrishnan A; Sahasrabuddhe NA; Mathur PP; Nair B; Keshava Prasad TS; Chang X; Sidransky D; Gowda H; Chatterjee A
Microrna; 2018; 7(1):38-53. PubMed ID: 29299995
[TBL] [Abstract][Full Text] [Related]
13. A high-quality secretome of A549 cells aided the discovery of C4b-binding protein as a novel serum biomarker for non-small cell lung cancer.
Luo X; Liu Y; Wang R; Hu H; Zeng R; Chen H
J Proteomics; 2011 Apr; 74(4):528-38. PubMed ID: 21262398
[TBL] [Abstract][Full Text] [Related]
14. Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins.
Jin Y; Wang J; Ye X; Su Y; Yu G; Yang Q; Liu W; Yu W; Cai J; Chen X; Liang Y; Chen Y; Wong BH; Fu X; Sun H
Br J Cancer; 2016 Mar; 114(5):532-44. PubMed ID: 26908325
[TBL] [Abstract][Full Text] [Related]
15. A new biomarker panel in bronchoalveolar lavage for an improved lung cancer diagnosis.
Uribarri M; Hormaeche I; Zalacain R; Lopez-Vivanco G; Martinez A; Nagore D; Ruiz-Argüello MB
J Thorac Oncol; 2014 Oct; 9(10):1504-12. PubMed ID: 25105437
[TBL] [Abstract][Full Text] [Related]
16. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.
Ostroff RM; Bigbee WL; Franklin W; Gold L; Mehan M; Miller YE; Pass HI; Rom WN; Siegfried JM; Stewart A; Walker JJ; Weissfeld JL; Williams S; Zichi D; Brody EN
PLoS One; 2010 Dec; 5(12):e15003. PubMed ID: 21170350
[TBL] [Abstract][Full Text] [Related]
17. Using feature selection and Bayesian network identify cancer subtypes based on proteomic data.
Wang Y; Gao X; Ru X; Sun P; Wang J
J Proteomics; 2023 May; 280():104895. PubMed ID: 37024076
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer.
Hu R; Huffman KE; Chu M; Zhang Y; Minna JD; Yu Y
J Proteome Res; 2016 Feb; 15(2):477-86. PubMed ID: 26736068
[TBL] [Abstract][Full Text] [Related]
19. LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma.
Yu C; Hou L; Cui H; Zhang L; Tan X; Leng X; Li Y
Future Oncol; 2018 Oct; 14(24):2483-2492. PubMed ID: 29756998
[TBL] [Abstract][Full Text] [Related]
20. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
Liu B; Chen Y; Yang J
Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
